TIDMDXRX
Diaceutics PLC
21 January 2021
21 January 2021
Diaceutics PLC
("Diaceutics" or "the Company")
Quarterly media update
Diaceutics PLC (AIM: DXRX) provides an overview to the market
for Q4 2020. The Company would like to issue an update of
non-regulatory news and coverage that has been achieved in the last
quarter of 2020 in order to keep investors abreast of the Company's
activities. This announcement contains a summary of key media
mentions and links to original pieces with examples, along with
some supporting highlights.
The launch of DXRX - The Diagnostic Network(R) has been very
successful, and Diaceutics cited 557 mentions* in the news during
Q4 with the launch of the platform.
-- 1 October 2020: 19 Organizations from the Healthcare
Community Unite to Form COVID-19 Testing Industry Consortium cited
in Media Outlets including; PR Newswire, BioSpace, Bloomberg, M2
Pharma and Market Screener
Examples include Bloomberg:
https://www.bloomberg.com/press-releases/2020-10-01/19-organizations-from-the-healthcare-community-unite-to-form-covid-19-testing-industry-consortium
-- 5 October 2020: Diaceutics Research Predicts NSCLC US Testing
Market to Reach $3.6bn by 2025, but Solution Still Needed to
Improve Patient Outcomes cited in Media Outlets including;
Nasdaq.com, Wallstreet Online, Bloomberg, Fox 21 Delmarva, Yahoo!
Finance
Examples include Yahoo! Finance:
https://finance.yahoo.com/news/diaceutics-research-predicts-nsclc-us-141000504.html
-- 28 October 2020: Diaceutics launches world's first Diagnostic
Network for Precision Medicine to solve global cancer testing
issues cited in Media Outlets including Silicon Valley Daily,
Sharecast.com, Stock Market Wire, Sync NI, FE InvestEgate,
BioWorld, Financial Times, Bloomberg, Yahoo! Finance
Examples include Financial Times:
https://markets.ft.com/data/announce/detail?dockey=600-202010281010BIZWIRE_USPRX____BW5588-1
-- 17 November 2020: Diaceutics wins European international
award for publicly listed companies cited in Media Outlets
including FE InvestEgate, Proactive Investors UK, Sync NI
Examples include Proactive Investors:
https://www.proactiveinvestors.co.uk/companies/news/934161/hybridan-small-cap-feast---afc-energy-bahamas-petroleum-altus-strategies-and-others-934161.html
-- 30 November 2020: Diaceutics, Alva10 Gathering Evidence Base
for Improving PD-L1 Test Reimbursement cited in Media Outlets
including 360Dx, Financial Times, Bloomberg, StreetInsider.com,
Yahoo! Finance
Examples include 360Dx:
https://www.360dx.com/reimbursement-news/diaceutics-alva10-gathering-evidence-base-improving-pd-l1-test-reimbursement
-- 22 December 2020: Diaceutics Appoints Seasoned Business
Leader Deborah Davis as Non-executive Chair cited in Media Outlets
including Financial Times, Bloomberg, StreetInsider.com, London
South East, Market Screener, StockMarketWire, NewsCision, FE
InvestEgate
Examples include Stock Market Wire:
https://www.sltockmarketwire.com/article/7188907/Diaceutics-appoints-Deborah-Davis-as-chair.html
Peter Keeling, CEO of Diaceutics commented: "We are pleased to
provide a comprehensive update to the market on all the news and
activity we have had that has not been issued through the
regulatory channels in the last quarter of 2020. Sometimes when
focusing purely on our RNS newsfeed, other media activity can be
missed and we feel it is important to give our valued investors and
potential new shareholders the opportunity to see a cross section
of other items we have released and the outcomes of those
announcements for their perusal. As a business, we are fortunate to
be performing well against the backdrop of the pandemic affecting
the global economy and we are glad to be able to share evidence of
this activity.
"Going forward, we will be issuing a similar update quarterly
and hope to have more key achievements as we move through the year.
The next statement will be due following the completion of Q1, in
April 2021."
*source - Meltwater
Enquiries:
Diaceutics PLC
Philip White, Chief Financial Officer Via Walbrook PR
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Tel: +44 (0)7876
741 001
Paul McManus Tel: +44 (0)7980
541 893
About Diaceutics
At Diaceutics we believe that every patient should get the
precision medicine they deserve. We are a data analytics and
end-to-end services provider enabled by DXRX - our Proprietary
Diagnostic Network solution for the development and
commercialisation of precision medicine diagnostics. The Company,
listed on the AIM Market of the London Stock Exchange, has created
commercially useful data sets for every precision medicine that has
come to market. We have built the world's largest repository of
diagnostic testing data with a growing network of 2,500
laboratories in 51 countries. www.diaceutics.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABIGDBIBDDGBG
(END) Dow Jones Newswires
January 21, 2021 02:00 ET (07:00 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024
